“…There is a striking correlation between conditions that impair axonal transport and conditions that activate DLK signaling: DLK signaling becomes activated in invertebrate and vertebrate PNS neurons that are treated with cytoskeletal destabilizing agents [47,48•,49,50], or with genetic mutations in the cytoskeletal components spectroplakin, TCP1, Tau, or spectrin [6,47,51•]. Activation also occurs in mutations that impair the kinesin Unc-104 (homologous to Kif1A), which is a major carrier of synaptic vesicle precursors in axons [24••]. Mutations that inhibit DLK signaling rescue the synaptic defects associated with mutations in the kinesin unc-104 [24••].…”